MIGENIX Inc. Second Quarter Fiscal 2006 Financial Results Conference Call & Web Cast Notification

VANCOUVER, BC, CANADA and SAN DIEGO, CA, USA, Dec. 1 /PRNewswire- FirstCall/ - MIGENIX Inc. , a clinical-stage developer of drugs for infectious and degenerative diseases, will host a conference call and web cast on Thursday, December 8, 2005 at 11:00 a.m. ET (8:00 a.m. PT) to discuss financial results for the second quarter of fiscal year 2006 ended October 31, 2005 and provide an update on company activities. To participate in the conference call, please dial 416-644-3424 or 1-800-814-4862. The call will be available for replay until December 22, 2005 by calling 416-640-1917 or 1-877-289-8525 and entering the pass code 21165871. The live and archived web cast can be accessed through the company's website at www.migenix.com.


MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic Hepatitis C infections (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I) and the treatment of acne (Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at www.migenix.com.

CONTACTS Jonathan Burke Dian Griesel, Ph.D. MIGENIX Inc. Investor Relations Group Tel: (604) 221-9666 Tel: (212) 825-3210 Extension 241 Theproteam@aol.comjburke@migenix.com

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.


CONTACT: Jonathan Burke, MIGENIX Inc., Tel: (604) 221-9666 Extension 241,jburke@migenix.com; Dian Griesel, Ph.D., Investor Relations Group, Tel:(212) 825-3210, Theproteam@aol.com; To request a free copy of thisorganization's annual report, please go to http://www.newswire.ca and clickon Tools for Investors.

Back to news